Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

A Protein kinase targeted.A number of these molecules are broad-spectrum kinase inhibitors.B Staurosporine class represents examples of broad-spectrum kinase inhibitors.PCD, preclinical development.These compounds may have progressed to phase I clinical trials.